Recursion Pharmaceuticals News - October 2026
🔴 Recursion Pharmaceuticals is trading 12.5% down today after $200 million discounted share offering
Recursion Pharmaceuticals is trading at $3.64, down 12.50%, as its discounted share offering raises dilution concerns. - The $200 million offering comprises...
Recursion Pharmaceuticals prices $200M offering and reports clinical progress in third quarter 2026
Recursion Pharmaceuticals announced a preliminary third quarter 2026 cash balance of approximately $561 million and the pricing of a $200 million underwritten...
Recursion's Triple-Barrel Announcement Lifts Shares 10% — But Can Clinical Promise Outrun Dilution?
Shares of Recursion Pharmaceuticals surged +10.4% to $4.13 as the AI-driven biotech orchestrated a carefully timed trifecta: updated trial data for two key...
🟢 Recursion Pharmaceuticals is trading 10.43% up today after REC-4881's 47% median polyp-burden reduction
Recursion Pharmaceuticals is trading at $4.13, up 10.43% in live trading, amid October 15 clinical updates. - REC-4881 updates included a 47% median reduction...
🟢 Recursion Pharmaceuticals is trading 5.48% up today amid trial updates and Sanofi's $10 million milestone
Recursion Pharmaceuticals is trading at $3.94, up 5.48%, amid October 15 clinical updates and a Sanofi milestone announcement. - Recursion reported...
🟢 Recursion Pharmaceuticals is trading 11% up today amid a 2.50% XBI gain
Recursion Pharmaceuticals is trading 10.51% higher at $4.37, alongside biotech-sector strength; the XBI is up 2.50%. - Positive sentiment also surrounds...
🔴 Recursion Pharmaceuticals is trading 10.2% down today amid biotech-sector weakness
Recursion Pharmaceuticals is trading 10.24% down at $3.83 amid biotech-sector weakness, with no clear company-specific catalyst identified for the October 8,...
Recursion's Tempus Deal Shrinks Its Cash Outflows and Licenses Its AI — But Can a $12 Million Side Deal Justify a 26% Weekly Rally?
Shares of Recursion Pharmaceuticals surged +6.3% to $5.08 on October 6, extending a blistering weekly run from $4.03 to over five dollars — a roughly 26% gain...
🟢 Recursion Pharmaceuticals jumps 6.3% with Cathie Wood's ARK Invest loading up shares, building on Tempus AI partnership optimism
Recursion Pharmaceuticals is trading at $5.08, up +6.28%, driven by fresh investment from Cathie Wood's ARK Invest and sustained optimism surrounding its...
🟢 Recursion Pharmaceuticals is trading 11% up today
Recursion Pharmaceuticals is trading at $4.56, up 10.61%, with no fresh company-specific announcement or clear catalyst identified for the October 5, 2026...